The combination of AFP & HCG is useful in classifying Germ Cell Tumors which may be predominantly one type of cell or a mixture of Seminoma, Yolk sac Tumor, Embryonal carcinoma and Teratoma. In 90% patients with Non seminomatous testicular tumors, one or both the markers may be elevated. Elevations were noted in <20% patients with stage I disease, 50-80% with stage II disease, and 90-100% with stage III disease. These markers correlate well with tumor volume and disease prognosis. Combined use of markers is useful in monitoring disease recurrence or development of metastasis. Lactate Dehydrogenase (LDH) is a nonspecific marker in malignancy but correlates well with tumor mass in solid tumors and is a good prognostic indicator of disease progression.